MA43168A - Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques - Google Patents
Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiquesInfo
- Publication number
- MA43168A MA43168A MA043168A MA43168A MA43168A MA 43168 A MA43168 A MA 43168A MA 043168 A MA043168 A MA 043168A MA 43168 A MA43168 A MA 43168A MA 43168 A MA43168 A MA 43168A
- Authority
- MA
- Morocco
- Prior art keywords
- carboxamide
- benzylpiperidin
- pyrazin
- piperazine
- antagonists
- Prior art date
Links
- NTEFDRIAFGEYBB-UHFFFAOYSA-N N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-pyrazin-2-ylpiperazine-1-carboxamide Chemical compound C(C1=CC=CC=C1)N1CCC(CC1)CCNC(=O)N1CCN(CC1)C1=NC=CN=C1 NTEFDRIAFGEYBB-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252179P | 2015-11-06 | 2015-11-06 | |
US201662275708P | 2016-01-06 | 2016-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43168A true MA43168A (fr) | 2018-09-12 |
Family
ID=57349137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043168A MA43168A (fr) | 2015-11-06 | 2016-11-04 | Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques |
Country Status (22)
Country | Link |
---|---|
US (2) | US11033539B2 (fr) |
EP (1) | EP3371164B1 (fr) |
JP (2) | JP6917989B2 (fr) |
KR (1) | KR20180073685A (fr) |
CN (1) | CN108349936B (fr) |
AU (1) | AU2016348524B2 (fr) |
BR (1) | BR112018008630A2 (fr) |
CA (1) | CA3001873A1 (fr) |
CL (1) | CL2018001217A1 (fr) |
CO (1) | CO2018004800A2 (fr) |
ES (1) | ES2915266T3 (fr) |
HK (1) | HK1253029A1 (fr) |
IL (1) | IL258862B (fr) |
MA (1) | MA43168A (fr) |
MX (1) | MX2018005215A (fr) |
MY (1) | MY194461A (fr) |
PE (1) | PE20181010A1 (fr) |
PH (1) | PH12018500940A1 (fr) |
SA (1) | SA518391518B1 (fr) |
SG (1) | SG11201803757UA (fr) |
TN (1) | TN2018000130A1 (fr) |
WO (1) | WO2017079641A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20181885A1 (es) | 2015-11-06 | 2018-12-07 | Hoffmann La Roche | Derivados de indolin-2-ona |
MY194461A (en) * | 2015-11-06 | 2022-11-30 | Neurocrine Biosciences Inc | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
JP2020530451A (ja) | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体m4のアンタゴニスト |
JP2020537667A (ja) | 2017-10-17 | 2020-12-24 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体m4のアンタゴニスト |
CN118063442A (zh) | 2017-10-20 | 2024-05-24 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
WO2019089676A1 (fr) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonistes du récepteur muscarinique m4 à l'acétylcholine |
US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
WO2019152809A1 (fr) * | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonistes du récepteur muscarinique de l'acétylcholine m4 |
EP3762368B1 (fr) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2020048826A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5 |
WO2020048827A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one |
WO2020048828A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane |
US20210155629A1 (en) * | 2018-09-04 | 2021-05-27 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
AU2020351178A1 (en) * | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders |
US20230046329A1 (en) | 2019-12-06 | 2023-02-16 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
JP2023512762A (ja) * | 2020-02-05 | 2023-03-29 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | ムスカリン性受容体4アンタゴニストおよび使用方法 |
WO2022156708A1 (fr) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Inhibiteur d'enzyme parp7 |
IL308228A (en) * | 2021-06-11 | 2024-01-01 | Neuronascent Inc | Methods and preparations for lipid formulation of lipophilic treatments small molecules of the heterocyclic type |
CN117957222A (zh) * | 2021-07-30 | 2024-04-30 | 纽罗克里生物科学有限公司 | 毒蕈碱受体4拮抗剂及使用方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
EP1553085A1 (fr) * | 1997-11-18 | 2005-07-13 | Teijin Limited | Dérivés d'amines cycliques et leur utilisation comme medicament |
NZ515374A (en) * | 1999-05-18 | 2004-09-24 | Teijin Ltd | Remedies or prophylactics for diseases in association with chemokines |
JP2003509494A (ja) * | 1999-09-22 | 2003-03-11 | シェーリング コーポレイション | ムスカリン拮抗薬 |
US20070010509A1 (en) * | 1999-12-08 | 2007-01-11 | Tatsuki Shiota | Cycloamine ccr5 receptor antagonists |
US6410566B1 (en) * | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
JPWO2003062234A1 (ja) | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
WO2004054974A2 (fr) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Antagonistes de ccr5 utiles comme agents therapeutiques |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
CN101426777A (zh) | 2005-12-21 | 2009-05-06 | 先灵公司 | 用作组胺h3拮抗剂的苯氧基哌啶及其类似物 |
WO2007130383A2 (fr) * | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions et traitements utilisant des pyridazines et des secrétases |
EP1997805A1 (fr) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compositions à activité antiparasite, applications associées au traitement des maladies infectieuses causées par des apicomplexans |
JP2013028538A (ja) * | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
CA2856759A1 (fr) | 2011-11-25 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | Derives 3-phenyl-isoquinolin-1(2h)-one en tant qu'inhibiteurs de parp-1 |
WO2014074517A1 (fr) * | 2012-11-08 | 2014-05-15 | Emory University | Compositions cellulaires utilisées pour la restauration de la fonction de cellules souches ou de cellules progénitrices et procédés associés |
JP2016505534A (ja) * | 2012-11-20 | 2016-02-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換1,6−ナフチリジン |
EP2976333B1 (fr) | 2013-03-18 | 2018-08-08 | Genoscience Pharma SAS | Dérivés de quinolines en tant que nouveaux agents anticancéreux |
US9598398B2 (en) * | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2014320149A1 (en) * | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
WO2015143380A1 (fr) | 2014-03-20 | 2015-09-24 | Samumed, Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
MY194461A (en) * | 2015-11-06 | 2022-11-30 | Neurocrine Biosciences Inc | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
-
2016
- 2016-11-04 MY MYPI2018000570A patent/MY194461A/en unknown
- 2016-11-04 ES ES16798333T patent/ES2915266T3/es active Active
- 2016-11-04 BR BR112018008630A patent/BR112018008630A2/pt not_active IP Right Cessation
- 2016-11-04 CA CA3001873A patent/CA3001873A1/fr not_active Abandoned
- 2016-11-04 CN CN201680064834.6A patent/CN108349936B/zh active Active
- 2016-11-04 EP EP16798333.7A patent/EP3371164B1/fr active Active
- 2016-11-04 PE PE2018000730A patent/PE20181010A1/es unknown
- 2016-11-04 MX MX2018005215A patent/MX2018005215A/es unknown
- 2016-11-04 JP JP2018522553A patent/JP6917989B2/ja active Active
- 2016-11-04 TN TNP/2018/000130A patent/TN2018000130A1/en unknown
- 2016-11-04 US US15/773,915 patent/US11033539B2/en active Active
- 2016-11-04 AU AU2016348524A patent/AU2016348524B2/en not_active Ceased
- 2016-11-04 SG SG11201803757UA patent/SG11201803757UA/en unknown
- 2016-11-04 KR KR1020187015620A patent/KR20180073685A/ko not_active Application Discontinuation
- 2016-11-04 MA MA043168A patent/MA43168A/fr unknown
- 2016-11-04 WO PCT/US2016/060659 patent/WO2017079641A1/fr active Application Filing
-
2018
- 2018-04-23 IL IL258862A patent/IL258862B/en active IP Right Grant
- 2018-05-02 PH PH12018500940A patent/PH12018500940A1/en unknown
- 2018-05-04 CL CL2018001217A patent/CL2018001217A1/es unknown
- 2018-05-04 CO CONC2018/0004800A patent/CO2018004800A2/es unknown
- 2018-05-05 SA SA518391518A patent/SA518391518B1/ar unknown
- 2018-09-27 HK HK18112407.2A patent/HK1253029A1/zh unknown
-
2021
- 2021-01-05 JP JP2021000354A patent/JP2021050243A/ja not_active Withdrawn
- 2021-04-26 US US17/239,726 patent/US20210338653A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2021050243A (ja) | 2021-04-01 |
AU2016348524A1 (en) | 2018-05-17 |
KR20180073685A (ko) | 2018-07-02 |
MX2018005215A (es) | 2018-08-01 |
SA518391518B1 (ar) | 2021-06-13 |
WO2017079641A1 (fr) | 2017-05-11 |
TN2018000130A1 (en) | 2019-10-04 |
IL258862B (en) | 2021-02-28 |
EP3371164A1 (fr) | 2018-09-12 |
CO2018004800A2 (es) | 2018-10-31 |
CN108349936A (zh) | 2018-07-31 |
IL258862A (en) | 2018-06-28 |
CN108349936B (zh) | 2021-10-01 |
AU2016348524B2 (en) | 2021-01-28 |
SG11201803757UA (en) | 2018-06-28 |
JP2018531981A (ja) | 2018-11-01 |
US20210338653A1 (en) | 2021-11-04 |
BR112018008630A2 (pt) | 2018-10-30 |
MY194461A (en) | 2022-11-30 |
US11033539B2 (en) | 2021-06-15 |
CL2018001217A1 (es) | 2018-08-03 |
CA3001873A1 (fr) | 2017-05-11 |
PE20181010A1 (es) | 2018-06-26 |
US20180325887A1 (en) | 2018-11-15 |
HK1253029A1 (zh) | 2019-06-06 |
ES2915266T3 (es) | 2022-06-21 |
EP3371164B1 (fr) | 2022-03-16 |
JP6917989B2 (ja) | 2021-08-11 |
PH12018500940A1 (en) | 2018-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43168A (fr) | Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA41841A (fr) | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs | |
MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
MA50786A (fr) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques | |
MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
MA53835A (fr) | Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires | |
MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
WO2016100162A3 (fr) | Antagonistes oxazoles 5,5-bicycliques du récepteur d'orexine | |
MA49664A (fr) | Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
FR24C1017I1 (fr) | Utilisations d'antagonistes d'il-13 pour le traitement de la dermatite atopique | |
IN2014CN02515A (fr) | ||
MA43817A (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
MA56047A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
EA201691997A1 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
MA52252A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
PL3464276T3 (pl) | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu | |
MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |